Van Lanschot Kempen Investment Management N.V. Buys 21,940 Shares of Eli Lilly and Company $LLY

Van Lanschot Kempen Investment Management N.V. raised its stake in Eli Lilly and Company (NYSE:LLY) by 76.2% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 50,744 shares of the company’s stock after purchasing an additional 21,940 shares during the period. Van Lanschot Kempen Investment Management N.V.’s holdings in Eli Lilly and Company were worth $41,910,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. PNC Financial Services Group Inc. increased its position in shares of Eli Lilly and Company by 97.5% during the first quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company’s stock worth $83,669,349,000 after acquiring an additional 50,002,551 shares in the last quarter. GAMMA Investing LLC increased its position in shares of Eli Lilly and Company by 103,831.6% during the first quarter. GAMMA Investing LLC now owns 14,866,380 shares of the company’s stock worth $12,278,292,000 after acquiring an additional 14,852,076 shares in the last quarter. Nuveen LLC bought a new stake in shares of Eli Lilly and Company during the first quarter worth about $4,613,912,000. Vanguard Group Inc. increased its position in shares of Eli Lilly and Company by 6.7% during the first quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company’s stock worth $65,432,218,000 after acquiring an additional 4,975,395 shares in the last quarter. Finally, Northern Trust Corp increased its position in shares of Eli Lilly and Company by 14.6% during the fourth quarter. Northern Trust Corp now owns 9,448,219 shares of the company’s stock worth $7,294,025,000 after acquiring an additional 1,204,337 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Analyst Ratings Changes

LLY has been the topic of several analyst reports. UBS Group cut their price target on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating on the stock in a report on Friday, August 8th. Leerink Partnrs cut shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 7th. Guggenheim cut their price target on shares of Eli Lilly and Company from $942.00 to $875.00 and set a “buy” rating on the stock in a report on Wednesday, August 13th. Leerink Partners restated a “market perform” rating and set a $715.00 price target on shares of Eli Lilly and Company in a report on Thursday, August 7th. Finally, Morgan Stanley restated an “overweight” rating and set a $1,135.00 price target (up from $1,133.00) on shares of Eli Lilly and Company in a report on Thursday, July 10th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $950.17.

Insider Transactions at Eli Lilly and Company

In related news, Director J Erik Fyrwald purchased 1,565 shares of the firm’s stock in a transaction dated Tuesday, August 12th. The shares were purchased at an average price of $642.33 per share, with a total value of $1,005,246.45. Following the acquisition, the director directly owned 74,578 shares of the company’s stock, valued at approximately $47,903,686.74. This represents a 2.14% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Daniel Skovronsky purchased 1,000 shares of the firm’s stock in a transaction dated Tuesday, August 12th. The stock was bought at an average cost of $634.40 per share, for a total transaction of $634,400.00. Following the acquisition, the executive vice president directly owned 137,660 shares in the company, valued at approximately $87,331,504. The trade was a 0.73% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders purchased 4,514 shares of company stock worth $2,894,841. 0.14% of the stock is owned by corporate insiders.

Eli Lilly and Company Stock Down 0.3%

Shares of NYSE:LLY opened at $698.89 on Tuesday. The firm has a fifty day moving average price of $763.06 and a two-hundred day moving average price of $793.64. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. Eli Lilly and Company has a one year low of $623.78 and a one year high of $972.53. The company has a market cap of $661.47 billion, a price-to-earnings ratio of 45.68, a PEG ratio of 0.98 and a beta of 0.44.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. During the same period last year, the firm earned $3.92 EPS. The business’s quarterly revenue was up 37.6% compared to the same quarter last year. Analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be issued a $1.50 dividend. This represents a $6.00 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend is Friday, August 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 39.22%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.